137 related articles for article (PubMed ID: 36279845)
1. Volumetric dried blood microsampling for monitoring imatinib mesylate therapy: Method development and clinical application in patients with chronic myeloid leukemia.
Krützmann ME; Martini RR; de Souza Guterres F; Kohlrausch R; Wagner SC; Mattevi VS; Torriani MS; Fogliatto LM; Linden R; Antunes MV
J Pharm Biomed Anal; 2023 Jan; 222():115108. PubMed ID: 36279845
[TBL] [Abstract][Full Text] [Related]
2. First report of imatinib measurement in hair: Method development and preliminary evaluation of the relation between hair and plasma concentrations with therapeutic response in chronic myeloid leukemia.
Capron A; Antunes MV; Wagner SC; Mattevi VS; Vieira N; Leite R; Reginato F; Capra M; Fogliatto L; Wallemacq P; Linden R
Clin Chim Acta; 2016 Jan; 453():42-7. PubMed ID: 26657979
[TBL] [Abstract][Full Text] [Related]
3. Use of total and unbound imatinib and metabolite LC-MS/MS assay to understand individual responses in CML and GIST patients.
Streit F; Binder L; Hafke A; Brandhorst G; Braulke F; Haase D; Armbrust T; Cameron S; Ramadori G; Oellerich M; Walson P
Ther Drug Monit; 2011 Oct; 33(5):632-43. PubMed ID: 21912334
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic Drug Monitoring of Imatinib and N-Desmethyl Imatinib in Chronic Myeloid Leukemia Patients Using LC-MS/MS in a Cohort Study.
Huang X; Liu Y; Chen J; Zheng H; Ding Y; He Z
J Clin Pharmacol; 2023 Dec; 63(12):1438-1447. PubMed ID: 37563838
[TBL] [Abstract][Full Text] [Related]
5. Volumetric absorptive microsampling (VAMS) for the quantification of ten kinase inhibitors and determination of their in vitro VAMS-to-plasma ratio.
Zimmermann S; Aghai F; Schilling B; Kraus S; Grigoleit GU; Kalogirou C; Goebeler ME; Jung P; Pelzer T; Klinker H; Isberner N; Scherf-Clavel O
J Pharm Biomed Anal; 2022 Mar; 211():114623. PubMed ID: 35121279
[TBL] [Abstract][Full Text] [Related]
6. Development of plasma cell leukemia in a patient with chronic myeloid leukemia while on treatment with imatinib mesylate.
Maral S; Bakanay SM; Yikilmaz AS; Dilek I
J Cancer Res Ther; 2018; 14(6):1431-1433. PubMed ID: 30488870
[TBL] [Abstract][Full Text] [Related]
7. [Nilotinib as a second-line treatment for chronic myeloid leukemia].
Yamauchi T; Ueda T
Gan To Kagaku Ryoho; 2011 Jun; 38(6):911-5. PubMed ID: 21677481
[TBL] [Abstract][Full Text] [Related]
8. A study to explore the correlation of ABCB1, ABCG2, OCT1 genetic polymorphisms and trough level concentration with imatinib mesylate-induced thrombocytopenia in chronic myeloid leukemia patients.
Francis J; Dubashi B; Sundaram R; Pradhan SC; Chandrasekaran A
Cancer Chemother Pharmacol; 2015 Dec; 76(6):1185-9. PubMed ID: 26546461
[TBL] [Abstract][Full Text] [Related]
9. Simultaneous Determination of Imatinib, Dasatinib, and Nilotinib by Liquid Chromatography-Tandem Mass Spectrometry and Its Application to Therapeutic Drug Monitoring.
Wojnicz A; Colom-Fernández B; Steegmann JL; Muñoz-Calleja C; Abad-Santos F; Ruiz-Nuño A
Ther Drug Monit; 2017 Jun; 39(3):252-262. PubMed ID: 28490048
[TBL] [Abstract][Full Text] [Related]
10. Imatinib pharmacokinetics and creatine kinase levels in chronic myeloid leukemia patients: implications for therapeutic response and monitoring.
Omran MM; Ibrahim AB; Abdelfattah R; Shouman SA; Hamza MS
Eur J Clin Pharmacol; 2024 Jul; 80(7):1061-1068. PubMed ID: 38536418
[TBL] [Abstract][Full Text] [Related]
11. Prevalence of BCR-ABL T315I Mutation in Malaysian Patients with Imatinib-Resistant Chronic Myeloid Leukemia.
Mat Yusoff Y; Abu Seman Z; Othman N; Kamaluddin NR; Esa E; Zulkiply NA; Abdullah J; Zakaria Z
Asian Pac J Cancer Prev; 2018 Dec; 19(12):3317-3320. PubMed ID: 30583336
[TBL] [Abstract][Full Text] [Related]
12. hOCT1 gene expression predict for optimal response to Imatinib in Tunisian patients with chronic myeloid leukemia.
Ben Hassine I; Gharbi H; Soltani I; Teber M; Farrah A; Ben Hadj Othman H; Amouri H; Bellaaj H; Lakhal RB; Romdhane NB; Abbes S; Menif S
Cancer Chemother Pharmacol; 2017 Apr; 79(4):737-745. PubMed ID: 28286932
[TBL] [Abstract][Full Text] [Related]
13. DBS sampling in imatinib therapeutic drug monitoring: from method development to clinical application.
Antunes MV; Raymundo S; Wagner SC; Mattevi VS; Vieira N; Leite R; Reginato F; Capra MZ; Fogliatto L; Linden R
Bioanalysis; 2015; 7(16):2105-17. PubMed ID: 26327189
[TBL] [Abstract][Full Text] [Related]
14. Aberrant DNA methylation at HOXA4 and HOXA5 genes are associated with resistance to imatinib mesylate among chronic myeloid leukemia patients.
Elias MH; Azlan H; Sulong S; Baba AA; Ankathil R
Cancer Rep (Hoboken); 2018 Aug; 1(2):e1111. PubMed ID: 32721103
[TBL] [Abstract][Full Text] [Related]
15. A Retrospective Study of Clinical Profile and Long Term Outcome to Imatinib Mesylate Alone in Childhood Chronic Myeloid Leukemia in Chronic Phase.
Department of Medical and Pediatric Oncology, The Gujarat Cancer and Research Institute, Ahmedabad, Gujarat. INDIA
Gulf J Oncolog; 2017 Jan; 1(23):15-20. PubMed ID: 28271997
[TBL] [Abstract][Full Text] [Related]
16. Reduced-intensity allogeneic hematopoietic stem cell transplantation combined with imatinib has comparable event-free survival and overall survival to long-term imatinib treatment in young patients with chronic myeloid leukemia.
Zhao Y; Wang J; Luo Y; Shi J; Zheng W; Tan Y; Cai Z; Huang H
Ann Hematol; 2017 Aug; 96(8):1353-1360. PubMed ID: 28624905
[TBL] [Abstract][Full Text] [Related]
17. ApoptomiRs expression modulated by BCR-ABL is linked to CML progression and imatinib resistance.
Ferreira AF; Moura LG; Tojal I; Ambrósio L; Pinto-Simões B; Hamerschlak N; Calin GA; Ivan C; Covas DT; Kashima S; Castro FA
Blood Cells Mol Dis; 2014; 53(1-2):47-55. PubMed ID: 24629639
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic drug monitoring of mycophenolic acid (MPA) using volumetric absorptive microsampling (VAMS) in pediatric renal transplant recipients: ultra-high-performance liquid chromatography-tandem mass spectrometry analytical method development, cross-validation, and clinical application.
Kocur A; Rubik J; Czarnowski P; Czajkowska A; Marszałek D; Sierakowski M; Górska M; Pawiński T
Pharmacol Rep; 2023 Aug; 75(4):1026-1042. PubMed ID: 37452967
[TBL] [Abstract][Full Text] [Related]
19. Clinical implications of conventional cytogenetics, fluorescence in situ hybridization (FISH) and molecular testing in chronic myeloid leukaemia patients in the tyrosine kinase inhibitor era - A review.
Ankathil R; Ismail SM; Mohd Yunus N; Sulong S; Husin A; Abdullah AD; Hassan R
Malays J Pathol; 2020 Dec; 42(3):307-321. PubMed ID: 33361712
[TBL] [Abstract][Full Text] [Related]
20. Volumetric absorptive microsampling as a suitable tool to monitor tyrosine kinase inhibitors.
Verougstraete N; Stove CP
J Pharm Biomed Anal; 2022 Jan; 207():114418. PubMed ID: 34655987
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
